Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma

被引：0

作者：

Chari, Ajai ^{[1
]}

Dimopoulos, Meletios-Athanasios ^{[2
]}

Beksac, Meral ^{[3
]}

Leleu, Xavier ^{[4
,5
]}

Weisel, Katja ^{[6
]}

Richter, Joshua ^{[7
]}

Dirnberger, Franziska ^{[8
]}

Iskander, Karim ^{[8
]}

Yusuf, Akeem ^{[8
]}

Mikhael, Joseph ^{[9
]}

机构：

[1] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA

[2] Natl & Kapodistrian Univ Athens, Dept Clin Therapeut, Sch Med, Alexandra Gen Hosp, Athens, Greece

[3] Ankara Univ, Ankara, Turkey

[4] CHU, Serv Hematol & Therapie Cellulaire, Poitiers, France

[5] CIC Inserm 1402, Poitiers, France

[6] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[7] Mt Sinai Hosp, Icahn Sch Med, New York, NY 10029 USA

[8] Amgen Inc, Thousand Oaks, CA 91320 USA

[9] City Hope Canc Ctr, Translat Genom Res Inst TGen, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-191

引用

页码：S142 / S142

页数：1

共 50 条

[31] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma. [J].

Yee, Andrew J. ;

Nadeem, Omar ;

Rosenblatt, Jacalyn ;

Bianchi, Giada ;

O'Donnell, Elizabeth ;

Branagan, Andrew R. ;

Harrington, Cynthia C. ;

Agyemang, Emerentia A. ;

Gammon, Marilyn T. ;

Lively, Kathleen J. ;

Packer, Lisette A. ;

Bernstein, Zachary S. ;

Lyons, Rebecca T. ;

Riadi, Manal ;

Rowell, Sean M. ;

Mcvey, Cailin ;

Goguen, Amy C. ;

Horick, Nora K. ;

Richardson, Paul G. ;

Raje, Noopur S. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[32] MonumenTAL-3: Phase 3 Trial of Talquetamab plus Daratumumab ± Pomalidomide Versus Daratumumab plus Pomalidomide plus Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy [J].

Cohen, Yael C. ;

Moreau, Philippe ;

Tolbert, Jaszianne ;

Qin, Xiang ;

Ma, Xuewen ;

Vieyra, Diego ;

Langlois, Angelique ;

Courtoux, Christelle ;

Terry, William ;

Pei, Lixia ;

Heuck, Christoph ;

Voorhees, Peter .

BLOOD, 2022, 140 :4418-4419

[33] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma [J].

Richardson, Paul G. ;

Facon, Thierry ;

Bensinger, William I. ;

Leleu, Xavier ;

Campana, Frank ;

Mace, Sandrine ;

Chiron, Marielle ;

van de Velde, Helgi ;

Mikhael, Joseph .

BLOOD CANCER JOURNAL, 2021, 11 (03)

[34] Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status. [J].

Weisel, Katja C. ;

Miguel, Jesus San ;

Cook, Gordon ;

Leiba, Merav ;

Suzuki, Kenshi ;

Kumar, Shaji ;

Cavo, Michele ;

Avet-Loiseau, Herve ;

Quach, Hang ;

Hungria, Vania ;

Lentzsch, Suzanne ;

Hajek, Roman ;

Sonneveld, Pieter ;

Wu, Kaida .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[35] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma [J].

Paul G. Richardson ;

Thierry Facon ;

William I. Bensinger ;

Xavier Leleu ;

Frank Campana ;

Sandrine Macé ;

Marielle Chiron ;

Helgi van de Velde ;

Joseph Mikhael .

Blood Cancer Journal, 11

[36] Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma [J].

Dosne, Anne-Gaelle ;

Li, Xia ;

Luo, Man Melody ;

Nnane, Ivo ;

Dimopoulos, Meletios A. ;

Terpos, Evangelos ;

Sonneveld, Pieter ;

Kampfenkel, Tobias ;

Carson, Robin ;

Amin, Himal ;

Ruixo, Juan Perez ;

Zhou, Honghui ;

Sun, Yu-Nien ;

Xu, Yan .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (05) :1640-1655

[37] Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study [J].

Dimopoulos, Meletios A. ;

Quach, Hang ;

Mateos, Maria-Victoria ;

Landgren, Ola ;

Leleu, Xavier ;

Siegel, David S. ;

Weisel, Katja ;

Gavriatopoulou, Maria ;

Oriol, Albert ;

Rabin, Neil K. ;

Nooka, Ajay ;

Qi, Ming ;

Ding, Bifeng ;

Zahlten-Kumeli, Anita ;

Usmani, Saad Z. .

BLOOD, 2020, 136

[38] Weekly Carfilzomib Combined with Daratumumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma [J].

Xu, Jiadai ;

Liu, Peng .

BLOOD, 2024, 144 :7052-7053

[39] Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM). [J].

Trudel, Suzanne ;

Beksac, Meral ;

Pour, Ludek ;

Delimpasi, Sosana ;

Quach, Hang ;

Vorobyev, Vladimir I. ;

Cavo, Michele ;

Suzuki, Kazuhito ;

Robak, Pawel ;

Morris, Kristin ;

Phillips-Jones, Amy ;

Zhou, Xiaoou Linnette ;

Fulci, Giulia ;

Sule, Neal ;

Kremer, Brandon ;

Opalinska, Joanna ;

Mateos, Maria-Victoria ;

Dimopoulos, Meletios Athanasios .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) :LBA105-LBA105

[40] Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin, Pomalidomide, Dexamethasone vs Pomalidomide Plus Bortezomib, Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma [J].

Trudel, Suzanne ;

Beksac, Meral ;

Pour, Ludek ;

Delimpasi, Sosana ;

Vorobyev, Vladimir ;

Hang Quach ;

Spicka, Ivan ;

Radocha, Jakub ;

Robak, Pawel ;

Kim, Kihyun ;

Cavo, Michele ;

Suzuki, Kazuhito ;

Morris, Kristin ;

Pompilus, Farrah ;

Wilkes, Jodie ;

Philips-Jones, Amy ;

Zhou, Xiaoou ;

Fulci, Giulia ;

Sule, Neal ;

Kremer, Brandon ;

Opalinska, Joanna ;

Mateos Manteca, Maria-Victoria ;

Dimopoulos, Meletios .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 :S39-S40

← 1 2 3 4 5 →